JNCE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
JNCE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Jounce Therapeutics's ROE % for the quarter that ended in Dec. 2022 was 130.47%. Jounce Therapeutics's PB Ratio for the quarter that ended in Dec. 2022 was 0.31. Jounce Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2022 was 420.87%.
The historical data trend for Jounce Therapeutics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jounce Therapeutics Annual Data | |||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | ||||||||||
ROE % Adjusted to Book Value | Get a 7-Day Free Trial | -18.87 | 24.12 | -16.46 | -21.87 | -80.74 |
Jounce Therapeutics Quarterly Data | ||||||||||||||||||||
Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
ROE % Adjusted to Book Value | Get a 7-Day Free Trial | -26.65 | -38.94 | -78.11 | -91.89 | 420.87 |
For the Biotechnology subindustry, Jounce Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Jounce Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Jounce Therapeutics's ROE % Adjusted to Book Value falls into.
Jounce Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as
Jounce Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Jounce Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Concentra Merger Sub, Inc. | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Concentra Biosciences, Llc | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Richard /ca/ Murray | director, officer: CEO and President | 22643 WOODRIDGE CT, CUPERTINO CA 95014 |
Kevin C Tang | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Tang Capital Partners Lp | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Tang Capital Management Llc | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Hugh M Cole | officer: Chief Business Officer | C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Elizabeth Trehu | officer: Chief Medical Officer | C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138 |
Kimberlee C Drapkin | officer: CFO and Treasurer | PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Third Rock Ventures Iii, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Jigar Raythatha | director | C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Third Rock Ventures Ii, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
John Duncan Higgons | director | C/O AGIOS PHARMACEUTICALS, INC., 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139 |
Luisa Salter-cid | director | C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121 |
Gilead Sciences Inc | 10 percent owner | 333 LAKESIDE DR, FOSTER CITY CA 94404 |
From GuruFocus
By PurpleRose PurpleRose • 08-04-2022
By sperokesalga sperokesalga • 03-27-2023
By PRNewswire PRNewswire • 02-23-2023
By GuruFocusNews GuruFocusNews • 05-17-2022
By Value_Insider Value_Insider • 11-02-2022
By PRNewswire PRNewswire • 02-28-2023
By sperokesalga sperokesalga • 03-27-2023
By GuruFocusNews GuruFocusNews • 06-06-2022
By GuruFocusNews GuruFocusNews • 05-27-2022
By PRNewswire PRNewswire • 03-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.